Induction of protective immunity against severe acute respiratory syndrome coronavirus (SARS-CoV) infection using highly attenuated recombinant vaccinia virus DIs

Virology

Volumn 351, Issue 2, 2006, Pages 368-380

  Ishii, Koji ^a   Hasegawa, Hideki ^a   Nagata, Noriyo ^a   Mizutani, Tetsuya ^a   Morikawa, Shigeru ^a   Suzuki, Tetsuro ^a   Taguchi, Fumihiro ^a   Tashiro, Masato ^a   Takemori, Toshitada ^a   Miyamura, Tatsuo ^a   Tsunetsugu Yokota, Yasuko ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

SARS; Vaccine; Vaccinia virus

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; EMBRYO; EXPERIMENTAL INFECTION; FEMALE; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION PREVENTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROVOCATION TEST; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; T LYMPHOCYTE ACTIVATION; VACCINATION; VACCINE PRODUCTION; VACCINIA VIRUS; VIRUS RECOMBINANT; VIRUS STRAIN;

ANIMALS; ANTIBODIES, VIRAL; CELL LINE; FEMALE; GENE EXPRESSION REGULATION, VIRAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; RECOMBINANT PROTEINS; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VACCINES, ATTENUATED; VACCINIA VIRUS; VIRAL VACCINES;

SARS CORONAVIRUS; VACCINIA VIRUS;

EID: 33746289555     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2006.03.020     Document Type: Article

References (53)

1. Anton I.M., Gonzalez S., Bullido M.J., Corsin M., Risco C., Langeveld J.P., and Enjuanes L. Cooperation between transmissible gastroenteritis coronavirus (TGEV) structural proteins in the in vitro induction of virus-specific antibodies. Virus Res. 46 1-2 (1996) 111-124
2. Belyakov I.M., Wyatt L.S., Ahlers J.D., Earl P., Pendleton C.D., Kelsall B.L., Strober W., Moss B., and Berzofsky J.A. Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein. J. Virol. 72 (1998) 8264-8272
3. Bisht H., Roberts A., Vogel L., Bukreyev A., Collins P.L., Murphy B.R., Subbarao K., and Moss B. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc. Natl. Acad. Sci. U. S. A. 101 17 (2004) 6641-6646
4. Buchholz U.J., Bukreyev A., Yang L., Lamirande E.W., Murphy B.R., Subbarao K., and Collins P.L. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc. Natl. Acad. Sci. U. S. A. 101 26 (2004) 9804-9809
5. Bukreyev A., Lamirande E.W., Buchholz U.J., Vogel L.N., Elkins W.R., St Claire M., Murphy B.R., Subbarao K., and Collins P.L. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 363 9427 (2004) 2122-2127
6. Collins A.R., Knobler R.L., Powell H., and Buchmeier M.J. Monoclonal antibodies to murine hepatitis virus-4 (strain JHM) define the viral glycoprotein responsible for attachment and cell-cell fusion. Virology 119 2 (1982) 358-371
7. Collisson E.W., Pei J., Dzielawa J., and Seo S.H. Cytotoxic T lymphocytes are critical in the control of infectious bronchitis virus in poultry. Dev. Comp. Immunol. 24 2-3 (2000) 187-200
8. Czub M., Weingartl H., Czub S., He R., and Cao J. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine 23 17-18 (2005) 2273-227 9
9. Drosten C., Gunther S., Preiser W., van der Werf S., Brodt H.R., Becker S., Rabenau H., Panning M., Kolesnikova L., Fouchier R.A., Berger A., Burguiere A.M., Cinatl J., Eickmann M., Escriou N., Grywna K., Kramme S., Manuguerra J.C., Muller S., Rickerts V., Sturmer M., Vieth S., Klenk H.D., Osterhaus A.D., Schmitz H., and Doerr H.W. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348 20 (2003) 1967-1976
10. Faber M., Lamirande E.W., Roberts A., Rice A.B., Koprowski H., Dietzschold B., and Schnell M.J. A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies. J. Gen. Virol. 86 Pt. 5 (2005) 1435-1440
11. Falkner F.G., and Moss B. Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors. J. Virol. 62 6 (1988) 1849-1854
12. Fouchier R.A., Kuiken T., Schutten M., van Amerongen G., van Doornum G.J., van den Hoogen B.G., Peiris M., Lim W., Stohr K., and Osterhaus A.D. Aetiology: Koch's postulates fulfilled for SARS virus. Nature 423 6937 (2003) 240
13. Gao W., Tamin A., Soloff A., D'Aiuto L., Nwanegbo E., Robbins P.D., Bellini W.J., Barratt-Boyes S., and Gambotto A. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 362 9399 (2003) 1895-1896
14. Groneberg D.A., Poutanen S.M., Low D.E., Lode H., Welte T., and Zabel P. Treatment and vaccines for severe acute respiratory syndrome. Lancet, Infect. Dis. 5 3 (2005) 147-155
15. Holmes K.V. SARS coronavirus: a new challenge for prevention and therapy. J. Clin. Invest. 111 11 (2003) 1605-1609
16. Ichinohe T., Watanabe I., Ito S., Fujii H., Moriyama M., Tamura S., Takahashi H., Sawa H., Chiba J., Kurata T., Sata T., and Hasegawa H. Synthetic double-stranded RNA poly (I:C) combined with mucosal vaccine protects against influenza virus infection. J. Virol. 79 5 (2005) 2910-2919
17. Ishii K., Ueda Y., Matsuo K., Matsuura Y., Kitamura T., Kato K., Izumi Y., Someya K., Ohsu T., Honda M., and Miyamura T. Structural analysis of vaccinia virus DIs strain: application as a new replication-deficient viral vector. Virology 302 2 (2002) 433-444
18. Jackwood M.W., and Hilt D.A. Production and immunogenicity of multiple antigenic peptide (MAP) constructs derived from the S1 glycoprotein of infectious bronchitis virus (IBV. Adv. Exp. Med. Biol. 380 (1995) 213-219
19. Kapadia S.U., Rose J.K., Lamirande E., Vogel L., Subbarao K., and Roberts A. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 340 (2005) 174-182
20. Kim T.W., Lee J.H., Hung C.F., Peng S., Roden R., Wang M.C., Viscidi R., Tsai Y.C., He L., Chen P.J., Boyd D.A., and Wu T.C. Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J. Virol. 78 9 (2004) 4638-4645
21. Kitamura T., Kitamura T., and Tagaya I. Immunogenicity of an attenuated strain of vaccinia virus on rabbits and monkeys. Nature 215 (1967) 1187-1188
22. Ksiazek T.G., Erdman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., Tong S., Urbani C., Comer J.A., Lim W., Rollin P.E., Dowell S.F., Ling A.E., Humphrey C.D., Shieh W.J., Guarner J., Paddock C.D., Rota P., Fields B., DeRisi J., Yang J.Y., Cox N., Hughes J.M., LeDuc J.W., Bellini W.J., and Anderson L.J. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348 20 (2003) 1953-1966
23. Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., Somasundaran M., Sullivan J.L., Luzuriaga K., Greenough T.C., Choe H., and Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426 6965 (2003) 450-454
24. Marra M.A., Jones S.J., Astell C.R., Holt R.A., Brooks-Wilson A., Butterfield Y.S., Khattra J., Asano J.K., Barber S.A., Chan S.Y., Cloutier A., Coughlin S.M., Freeman D., Girn N., Griffith O.L., Leach S.R., Mayo M., McDonald H., Montgomery S.B., Pandoh P.K., Petrescu A.S., Robertson A.G., Schein J.E., Siddiqui A., Smailus D.E., Stott J.M., Yang G.S., Plummer F., Andonov A., Artsob H., Bastien N., Bernard K., Booth T.F., Bowness D., Czub M., Drebot M., Fernando L., Flick R., Garbutt M., Gray M., Grolla A., Jones S., Feldmann H., Meyers A., Kabani A., Li Y., Normand S., Stroher U., Tipples G.A., Tyler S., Vogrig R., Ward D., Watson B., Brunham R.C., Krajden M., Petric M., Skowronski D.M., Upton C., and Roper R.L. The Genome sequence of the SARS-associated coronavirus. Science 300 5624 (2003) 1399-1404
25. Meeusen E.N., Scheerlinck J.P., Wattegedera S., and Entrican G. Advances in mucosal vaccination. Anim. Health Res. Rev. 5 2 (2004) 209-217
26. Mizutani T., Fukushi S., Saijo M., Kurane I., and Morikawa S. Phosphorylation of p38 MAPK and its downstream targets in SARS coronavirus-infected cells. Biochem. Biophys. Res. Commun. 319 4 (2004) 1228-1234
27. Nal B., Chan C., Kien F., Siu L., Tse J., Chu K., Kam J., Staropoli I., Crescenzo-Chaigne B., Escriou N., van der Werf S., Yuen K.Y., and Altmeyer R. Differential maturation and subcellular localization of severe acute respiratory syndrome coronavirus surface proteins S, M and E. J. Gen. Virol. 86 Pt. 5 (2005) 1423-1434
28. Nam J.H., Wyatt L.S., Chae S.L., Cho H.W., Park Y.K., and Moss B. Protection against lethal Japanese encephalitis virus infection of mice by immunization with the highly attenuated MVA strain of vaccinia virus expressing JEV prM and E genes. Vaccine 17 3 (1999) 261-268
29. Ohnishi K., Sakaguchi M., Kaji T., Akagawa K., Taniyama T., Kasai M., Tsunetsugu-Yokota Y., Oshima M., Yamamoto K., Takasuka N., Hashimoto S., Ato M., Fujii H., Takahashi Y., Morikawa S., Ishii K., Sata T., Takagi H., Itamura S., Odagiri T., Miyamura T., Kurane I., Tashiro M., Kurata T., Yoshikura H., and Takemori T. Immunological detection of severe acute respiratory syndrome coronavirus by monoclonal antibodies. Jpn. J. Infect. Dis. 58 2 (2005) 88-94
30. Peiris J.S., Lai S.T., Poon L.L., Guan Y., Yam L.Y., Lim W., Nicholls J., Yee W.K., Yan W.W., Cheung M.T., Cheng V.C., Chan K.H., Tsang D.N., Yung R.W., Ng T.K., and Yuen K.Y. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361 9366 (2003) 1319-1325
31. Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R., Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.H., Tong S., Tamin A., Lowe L., Frace M., DeRisi J.L., Chen Q., Wang D., Erdman D.D., Peret T.C., Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S., Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R., Gunther S., Osterhaus A.D., Drosten C., Pallansch M.A., Anderson L.J., and Bellini W.J. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300 5624 (2003) 1394-1399
32. Ruan Y.J., Wei C.L., Ee A.L., Vega V.B., Thoreau H., Su S.T., Chia J.M., Ng P., Chiu K.P., Lim L., Zhang T., Peng C.K., Lin E.O., Lee N.M., Yee S.L., Ng L.F., Chee R.E., Stanton L.W., Long P.M., and Liu E.T. Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet 361 9371 (2003) 1779-1785
33. Seo S.H., Wang L., Smith R., and Collisson E.W. The carboxyl-terminal 120-residue polypeptide of infectious bronchitis virus nucleocapsid induces cytotoxic T lymphocytes and protects chickens from acute infection. J. Virol. 71 10 (1997) 7889-7894
34. Someya K., Xin K.Q., Matsuo K., Okuda K., Yamamoto N., and Honda M. A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity. J. Virol. 78 18 (2004) 9842-9853
35. Stittelaar K.J., Wyatt L.S., de Swart R.L., Vos H.W., Groen J., van Amerongen G., van Binnendijk R.S., Rozenblatt S., Moss B., and Osterhaus A.D. Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies. J. Virol. 74 (2000) 4236-4243
36. Storch G.A. Diagnostic virology. In: David P.M.H., and Knipe M. (Eds). Fields Virology. 4th ed. (2001), Lippincott Williams & Wilkins, Philadelphia, PA 493-531
37. Subbarao K., McAuliffe J., Vogel L., Fahle G., Fischer S., Tatti K., Packard M., Shieh W.J., Zaki S., and Murphy B. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J. Virol. 78 7 (2004) 3572-3577
38. Sutter G., and Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 10847-10851
39. Sutter G., Wyatt L.S., Foley P.L., Bennink J.R., and Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12 (1994) 1032-1040
40. Tagaya I., Kitamura T., and Sano Y. A new mutant of dermovaccinia virus. Nature 192 (1961) 381-382
41. Takasuka N., Fujii H., Takahashi Y., Kasai M., Morikawa S., Itamura S., Ishii K., Sakaguchi M., Ohnishi K., Ohshima M., Hashimoto S., Odagiri T., Tashiro M., Yoshikura H., Takemori T., and Tsunetsugu-Yokota Y. A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Int. Immunol. 16 10 (2004) 1423-1430
42. Weingartl H., Czub M., Czub S., Neufeld J., Marszal P., Gren J., Smith G., Jones S., Proulx R., Deschambault Y., Grudeski E., Andonov A., He R., Li Y., Copps J., Grolla A., Dick D., Berry J., Ganske S., Manning L., and Cao J. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J. Virol. 78 22 (2004) 12672-12676
43. Weisz O.A., Swift A.M., and Machamer C.E. Oligomerization of a membrane protein correlates with its retention in the Golgi complex. J. Cell Biol. 122 6 (1993) 1185-1196
44. Wyatt L.S., Shors S.T., Murphy B.R., and Moss B. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 14 15 (1996) 1451-1458
45. Xiao X., Chakraborti S., Dimitrov A.S., Gramatikoff K., and Dimitrov D.S. The SARS-CoV S glycoprotein: expression and functional characterization. Biochem. Biophys. Res. Commun. 312 4 (2003) 1159-11564
46. Yang Z.Y., Kong W.P., Huang Y., Roberts A., Murphy B.R., Subbarao K., and Nabel G.J. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428 6982 (2004) 561-564
47. Yang Z.Y., Werner H.C., Kong W.P., Leung K., Traggiai E., Lanzavecchia A., and Nabel G.J. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc. Natl. Acad. Sci. U. S. A. 102 3 (2005) 797-801
48. Yoshizawa I., Soda Y., Mizuochi T., Yasuda S., Rizvi T.A., Takemori T., and Tsunetsugu-Yokota Y. Enhancement of mucosal immune response against HIV-1 Gag by DNA immunization. Vaccine 19 20-22 (2001) 2995-3003
49. You J., Dove B.K., Enjuanes L., DeDiego M.L., Alvarez E., Howell G., Heinen P., Zambon M., and Hiscox J.A. Subcellular localization of the severe acute respiratory syndrome coronavirus nucleocapsid protein. J. Gen. Virol. 86 Pt. 12 (2005) 3303-3310
50. Zakhartchouk A.N., Viswanathan S., Mahony J.B., Gauldie J., and Babiuk L.A. Severe acute respiratory syndrome coronavirus nucleocapsid protein expressed by an adenovirus vector is phosphorylated and immunogenic in mice. J. Gen. Virol. 86 Pt. 1 (2005) 211-215
51. Zhao P., Cao J., Zhao L.J., Qin Z.L., Ke J.S., Pan W., Ren H., Yu J.G., and Qi Z.T. Immune responses against SARS-coronavirus nucleocapsid protein induced by DNA vaccine. Virology 331 1 (2005) 128-135
52. Zhi Y., Kobinger G.P., Jordan H., Suchma K., Weiss S.R., Shen H., Schumer G., Gao G., Boyer J.L., Crystal R.G., and Wilson J.M. Identification of murine CD8 T cell epitopes in codon-optimized SARS-associated coronavirus spike protein. Virology 335 1 (2005) 34-45
53. Zhu M.S., Pan Y., Chen H.Q., Shen Y., Wang X.C., Sun Y.J., and Tao K.H. Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine. Immunol. Lett. 92 3 (2004) 237-243